{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:25:24Z","timestamp":1785241524191,"version":"3.55.0"},"reference-count":80,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"China Pharmaceutical University initiative program"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.1080\/13543776.2022.2034786","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T22:04:53Z","timestamp":1643234693000},"page":"153-170","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013\u20132021)"],"prefix":"10.1080","volume":"32","author":[{"given":"Xiangying","family":"Yu","sequence":"first","affiliation":[{"name":"School of Life Science & Technology, China Pharmaceutical University, Nanjing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Medicinal & Chemistry, China Pharmaceutical University, Nanjing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Institute of Medicinal & Chemistry, China Pharmaceutical University, Nanjing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Kong","sequence":"additional","affiliation":[{"name":"School of Life Science & Technology, China Pharmaceutical University, Nanjing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61652-4"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225629"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406682102"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13455"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0158-4"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1038\/35092573"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610188104"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.01944.x"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-06-0418"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00783.x"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2010.38"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1470"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3615"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1042\/bj20030954"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1021\/bi700597p"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.12.6642"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1038\/353674a0"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0704409104"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1021\/bi801334s"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2013.10.037"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3629"},{"key":"cit0022","first-page":"245","volume":"53","author":"Scott R","year":"2001","journal-title":"Pharmacol Rev"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15046169"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.01.003"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2017.04.006"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004634"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1124\/mol.116.106526"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4226.bloodjournal84124226"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1021\/jm010001h"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2007.10.070"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.08.021"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065528"},{"key":"cit0033","first-page":"1","volume-title":"Progress in medicinal chemistry","volume":"50","author":"Smith GF","year":"2011"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.10.020"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00186"},{"key":"cit0036","unstructured":"Banville J, Remillard R, Ruediger EH, et al. inventors; Bristol-Myers Squibb Company, USA; Universite de Montreal. assignee. Preparation of imidazothiadiazole derivatives and analogs for use as protease activated receptor 4 inhibitors patent WO2013163279A1. 2013.** The first patent to report the structure and biological activity data of BMS986120 and BMS986141.** The first patent to report the structure and biological activity data of BMS986120 and BMS986141."},{"key":"cit0037","unstructured":"Kornacker MG, Mapelli C, Riexinger DJ. inventors; Bristol-Myers Squibb Company, USA. assignee. Preparation of protease activated receptor 4 (PAR4) agonist peptides and their use as PAR4 receptor activation for measuring the activity of PAR4 antagonist imidazothiadiazole and imidazopyridazine derivatives and analogs patent WO2013163248A1. 2013."},{"key":"cit0038","unstructured":"Lawrence MR, Miller MM, Seiffert DA, et al. inventors; Bristol-Myers Squibb Company, USA; Universite de Montreal. assignee. Preparation of imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation patent WO2013163244A1. 2013."},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf5294"},{"key":"cit0040","unstructured":"ClinicalTrial. gov, Multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of BMS-986120 in healthy subjects and the effects of co-administration of midazolam and BMS-986120. [cited 10 Sept. 2021]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02208882"},{"key":"cit0041","unstructured":"ClinicalTrials. gov. CV004-007 thrombosis chamber study. [cited 10 Sept. 2021]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02439190"},{"key":"cit0042","unstructured":"Springer Nature Switzerland Ag Adis insight. [cited 10 Sept. 2021]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800041027"},{"key":"cit0043","first-page":"A13794","volume":"136","author":"Wong PC","year":"2017","journal-title":"Circulation"},{"key":"cit0044","unstructured":"ClinicalTrials gov. A study to evaluate the effect of diltiazem on the pharmacokinetics(PK) of BMS-986141 in healthy subjects. [cited 15 Sept. 2021]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02922452"},{"key":"cit0045","unstructured":"ClinicalTrials gov. A study to evaluate the pharmacokinetics of BMS-986141in participants with hepatic impairment compared to healthy participants. [cited 15 Sept. 2021]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02985632"},{"key":"cit0046","unstructured":"clinicaltrials gov. A study to evaluate the effect of rifampin on the single dose pharmacokinetics (PK) of BMS-986141 in healthy subjects. [cited 15 Sept. 2021]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02957448"},{"key":"cit0047","unstructured":"ClinicalTrials gov. Single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BMS-986141 in healthy subjects. [cited 15 Sept. 2021]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02341638"},{"key":"cit0048","unstructured":"ClinicalTrials gov. Evaluate the bioavailability between 2 BMS-986141 formulations in healthy participants. [cited 15 Sept. 2021]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03035734"},{"key":"cit0049","unstructured":"ClinicalTrials gov. Safety and efficacy study of a protease activated receptor-4 antagonist being tested to reduce the chances of having additional strokes or \u2019mini strokes\u2019. [cited 15 Sept. 2021]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02671461"},{"key":"cit0050","unstructured":"Priestley ES, Posy SL, Tremblay FT, et al. inventors; Bristol-Myers Squibb Company, USA; Universite de Montreal. assignee. Preparation of imidazothiadiazole derivatives and analogs for use as protease activated receptor 4 inhibitors patent WO2013163241A1. 2013."},{"key":"cit0051","unstructured":"Banville J. inventor; Universite de Montreal, Can. assignee. Imidazopyridazine and imidazothiadiazole compounds as PAR1 and PAR4 agonists for the treatment of thromboembolic disorders and their preparation patent WO2016134450A1. 2016."},{"key":"cit0052","unstructured":"Ruediger EH, Deon DH, Gagnon M, et al. inventors; bristol-myers squibb company, USA; Universite de Montreal. assignee. Preparation of benzothiazole and benzothiophene compounds as PAR4 antagonists patent WO2016138199A1. 2016."},{"key":"cit0053","unstructured":"Martel A, Tremblay F. inventors; Universite de Montreal, Can. assignee. Heterocyclic compounds as inhibitors of platelet aggregation and their preparation patent WO2017066863A1. 2017."},{"key":"cit0054","unstructured":"Martel A, Tremblay F. inventors; Universite de Montreal, Can. assignee. Preparation of imidazotriazine derivatives and analogs for use as platelet aggregation inhibitors patent US9598419B1. 2017."},{"key":"cit0055","unstructured":"Hamm HE, Stauffer SR, Lindsley CW, et al. inventors; Vanderbilt University, USA. assignee. Substituted and fused 6-membered protease activated receptor 4 (PAR-4) antagonists patent WO2017184520A1. 2017."},{"key":"cit0056","unstructured":"Hamm HE, Stauffer SR, Lindsley CW, et al. inventors; Vanderbilt University, USA. assignee. Preparation of substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists patent US20170253617A1. 2017."},{"key":"cit0057","unstructured":"Hamm HE, Stauffer SR, Lindsley CW, et al. inventors; Vanderbilt University, USA. assignee. Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists patent US20160083363A1. 2016."},{"key":"cit0058","unstructured":"Bray PF. inventor; Thomas Jefferson University, USA. assignee. Non-selective protease activated receptor 4 Ala120THR isoform antagonist patent WO2017066661A1. 2017."},{"key":"cit0059","unstructured":"Richter JM, Zhang X, Priestley ES. inventors; Bristol-Myers Squibb Company, USA. assignee. Preparation of monocyclic heteroaryl substituted compounds for inhibiting or preventing platelet aggregation patent WO2018013772A1. 2018."},{"key":"cit0060","unstructured":"Zhang X, Zheng X, Chupak LS. inventors; Bristol-Myers Squibb Company, USA. assignee. Aryl-substituted bicyclic heteroaryl compounds as PAR4 inhibitors and their preparation patent WO2017019828A1. 2017."},{"key":"cit0061","unstructured":"Fu Q, Zhang X, Priestley ES, et al. inventors; Bristol-Myers Squibb Company, USA. assignee. Preparation of bicyclic heteroaryl substituted compounds as PAR4 inhibitors patent WO2018013770A1. 2018."},{"key":"cit0062","unstructured":"Zhang X, Priestley ES, Bates JA, et al. inventors; bristol-myers squibb company, USA. assignee. Preparation of bicyclic heteroaryl substituted compounds as PAR4 inhibitors patent WO2018013774A1. 2018."},{"key":"cit0063","unstructured":"Zhang X, Priestley ES, Halpern OS, et al. inventors; Bristol-Myers Squibb Company, USA. assignee. Preparation of tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors patent WO2018013776A1. 2018."},{"key":"cit0064","unstructured":"Wu J, Li S, Wen X, et al. inventors; Shenzhen Salubris Pharmaceuticals Co. Ltd., Peop. Rep. China. assignee. Compound as protease activated receptor 4 (par4) inhibitor for treating platelet aggregation patent WO2019218955A1. 2019."},{"key":"cit0065","unstructured":"Wu J, Li S, Wen X, et al. inventors; Shenzhen Salubris Pharmaceuticals Co., Ltd., Peop. Rep. China. assignee. Compound acting as protease-activated receptor 4 inhibitor for treating platelet aggregation patent WO2019218956A1. 2019."},{"key":"cit0066","unstructured":"Wu J, Li S, Wen X, et al. inventors; Shenzhen Salubris Pharmaceuticals Co., Ltd., Peop. Rep. China. assignee. Preparation of imidazothiadiazole compounds useful as protease activated receptor 4 (PAR4) inhibitor for treating platelet aggregation patent WO2019218957A1. 2019."},{"key":"cit0067","unstructured":"Huang W, Jiang H, Yang H, et al. inventors; shanghai institute of materia medica, Chinese academy of sciences, Peop. Rep. China; East China normal University. assignee. Indolone compound, and its preparation method, pharmaceutical composition and application patent CN110818611A. 2020."},{"key":"cit0068","unstructured":"Yang F, Zhang L, Han J, et al. inventors; Jiangsu Hengrui Medicine Co., Ltd., Peop. Rep. China; shanghai hengrui pharmaceutical Co., Ltd. assignee. Benzoheteroaryl derivative and preparation method and medical application thereof patent WO2019149205A1. 2019."},{"key":"cit0069","unstructured":"Yang F, Fan X, Wang Y, et al. inventors; Jiangsu Hengrui Medicine Co., Ltd., Peop. Rep. China; Shanghai Hengrui Pharmaceutical Co., Ltd. assignee. Preparation of benzofuran derivative as PAR-4 antagonist patent CN110218218A. 2019."},{"key":"cit0070","unstructured":"Zhu X, Liu S, Kong Y, et al. inventors; China Pharmaceutical University, Peop. Rep. China. assignee. Benzotriazine compound with PAR4 antagonistic activity and application thereof in preparation of drug for preventing and\/or treating thromboembolic disease patent CN111440146A. 2020."},{"key":"cit0071","unstructured":"Zhu X, Liu S, Kong Y, et al. inventors; China Pharmaceutical University, Peop. Rep. China. assignee. Bicyclic heteroaryl compounds with protease activated receptor 4 (PAR4) antagonistic activity for drugs to prevent or treat thromboembolic disease patent CN111440161A. 2020."},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112893"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1139\/y01-013"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705946"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.022460899"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.587758"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12619"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.03.027"},{"key":"cit0079","unstructured":"Hamilton J, Sleeman M. inventors; Monash University, AU. assignee. Binding proteins to the human thrombin receptor, PAR4 patent WO2019046912A1. 2019."},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017015552"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2022.2034786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T12:23:16Z","timestamp":1645705396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2022.2034786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"alternative-id":["10.1080\/13543776.2022.2034786"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2022.2034786","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}